Do analysts prefer DYNT or PFSA?

Given Dynatronics' higher possible upside, equities research analysts clearly believe Dynatronics is more favorable than Profusa. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dynatronics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, DYNT or PFSA?

Dynatronics has higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dynatronics $33.60M 0.00 -$2.70M -$1.35 N/A Profusa N/A N/A -$35.82M -$4.24 thousand N/A

Is DYNT or PFSA more profitable?

Profusa has a net margin of 0.00% compared to Dynatronics' net margin of -8.35%. Profusa's return on equity of 0.00% beat Dynatronics' return on equity. Company Net Margins Return on Equity Return on Assets Dynatronics -8.35% -41.81% -9.56% Profusa N/A N/A -1,348.07%

Do analysts recommend BIOL or PFSA?

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Profusa. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, BIOL or PFSA?

BIOLASE has higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A Profusa N/A N/A -$35.82M -$4.24 thousand N/A

Is BIOL or PFSA more profitable?

Profusa has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Profusa's return on equity of 0.00% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Profusa N/A N/A -1,348.07%

Do analysts recommend PFSA or RBOT?

Vicarious Surgical has a consensus price target of $7.00, suggesting a potential upside of 10,285.76%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts plainly believe Vicarious Surgical is more favorable than Profusa. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vicarious Surgical 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher valuation & earnings, PFSA or RBOT?

Vicarious Surgical is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profusa N/A N/A -$35.82M -$4.24 thousand N/A Vicarious Surgical N/A N/A -$63.22M -$6.69 N/A

Is PFSA or RBOT more profitable?

Profusa's return on equity of 0.00% beat Vicarious Surgical's return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,348.07% Vicarious Surgical N/A -184.13% -112.50%

Do analysts prefer PFSA or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, PFSA or VERO?

Profusa has higher earnings, but lower revenue than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profusa N/A N/A -$35.82M -$4.24 thousand N/A Venus Concept $58.88M 0.01 -$47M -$48.84 N/A

Is PFSA or VERO more profitable?

Profusa has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Profusa's return on equity of 0.00% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,348.07% Venus Concept -92.76% -1,904.25% -85.22%

Do analysts prefer PFSA or NUWE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, PFSA or NUWE?

Nuwellis has higher revenue and earnings than Profusa. Nuwellis is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profusa N/A N/A -$35.82M -$4.24 thousand N/A Nuwellis $8.77M 0.32 -$17.52M -$2.24 thousand N/A

Is PFSA or NUWE more profitable?

Profusa has a net margin of 0.00% compared to Nuwellis' net margin of -214.90%. Profusa's return on equity of 0.00% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,348.07% Nuwellis -214.90% -32,351.83% -249.08%

Does the media refer more to PFSA or NUWE?

In the previous week, Profusa had 1 more articles in the media than Nuwellis. MarketBeat recorded 4 mentions for Profusa and 3 mentions for Nuwellis. Profusa's average media sentiment score of 0.98 beat Nuwellis' score of 0.00 indicating that Profusa is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Profusa 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuwellis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Profusa (PFSA) Competitors

$0.96 +0.02 (+2.53%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$0.96 -0.01 (-0.81%)

As of 08/7/2026 07:34 PM Eastern

Compare

PFSA vs. DYNT, BIOL, RBOT, VERO, and NUWE

Should you buy Profusa stock or one of its competitors? MarketBeat compares Profusa with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Profusa include Dynatronics (DYNT), BIOLASE (BIOL), Vicarious Surgical (RBOT), Venus Concept (VERO), and Nuwellis (NUWE). These companies are all part of the "healthcare equipment" industry.

How does Profusa compare to Dynatronics?

Dynatronics (NASDAQ:DYNT) and Profusa (NASDAQ:PFSA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Given Dynatronics' higher possible upside, equities research analysts clearly believe Dynatronics is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dynatronics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Profusa has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

Profusa has a net margin of 0.00% compared to Dynatronics' net margin of -8.35%. Profusa's return on equity of 0.00% beat Dynatronics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dynatronics	-8.35%	-41.81%	-9.56%
Profusa	N/A	N/A	-1,348.07%

In the previous week, Profusa had 4 more articles in the media than Dynatronics. MarketBeat recorded 4 mentions for Profusa and 0 mentions for Dynatronics. Profusa's average media sentiment score of 0.98 beat Dynatronics' score of 0.00 indicating that Profusa is being referred to more favorably in the news media.

Company	Overall Sentiment
Dynatronics	Neutral
Profusa	Positive

Dynatronics has higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A
Profusa	N/A	N/A	-$35.82M	-$4.24 thousand	N/A

4.2% of Dynatronics shares are owned by institutional investors. Comparatively, 9.8% of Profusa shares are owned by institutional investors. 2.9% of Dynatronics shares are owned by insiders. Comparatively, 0.8% of Profusa shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Profusa beats Dynatronics on 8 of the 14 factors compared between the two stocks.

How does Profusa compare to BIOLASE?

BIOLASE (NASDAQ:BIOL) and Profusa (NASDAQ:PFSA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

In the previous week, Profusa had 4 more articles in the media than BIOLASE. MarketBeat recorded 4 mentions for Profusa and 0 mentions for BIOLASE. Profusa's average media sentiment score of 0.98 beat BIOLASE's score of 0.00 indicating that Profusa is being referred to more favorably in the news media.

Company	Overall Sentiment
BIOLASE	Neutral
Profusa	Positive

BIOLASE has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Profusa has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

BIOLASE has higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Profusa	N/A	N/A	-$35.82M	-$4.24 thousand	N/A

Profusa has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Profusa's return on equity of 0.00% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Profusa	N/A	N/A	-1,348.07%

8.8% of BIOLASE shares are owned by institutional investors. Comparatively, 9.8% of Profusa shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by insiders. Comparatively, 0.8% of Profusa shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BIOLASE and Profusa tied by winning 7 of the 14 factors compared between the two stocks.

How does Profusa compare to Vicarious Surgical?

Profusa (NASDAQ:PFSA) and Vicarious Surgical (NYSE:RBOT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Vicarious Surgical has a consensus price target of $7.00, suggesting a potential upside of 10,285.76%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts plainly believe Vicarious Surgical is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Vicarious Surgical is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	N/A	N/A	-$35.82M	-$4.24 thousand	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

Profusa has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

In the previous week, Profusa had 4 more articles in the media than Vicarious Surgical. MarketBeat recorded 4 mentions for Profusa and 0 mentions for Vicarious Surgical. Profusa's average media sentiment score of 0.98 beat Vicarious Surgical's score of 0.00 indicating that Profusa is being referred to more favorably in the media.

Company	Overall Sentiment
Profusa	Positive
Vicarious Surgical	Neutral

9.8% of Profusa shares are held by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are held by institutional investors. 0.8% of Profusa shares are held by company insiders. Comparatively, 11.1% of Vicarious Surgical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profusa's return on equity of 0.00% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,348.07%
Vicarious Surgical	N/A	-184.13%	-112.50%

Summary

Vicarious Surgical beats Profusa on 7 of the 12 factors compared between the two stocks.

How does Profusa compare to Venus Concept?

Profusa (NASDAQ:PFSA) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Profusa has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Profusa's return on equity of 0.00% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,348.07%
Venus Concept	-92.76%	-1,904.25%	-85.22%

9.8% of Profusa shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 0.8% of Profusa shares are held by insiders. Comparatively, 28.0% of Venus Concept shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profusa has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Profusa has higher earnings, but lower revenue than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	N/A	N/A	-$35.82M	-$4.24 thousand	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

In the previous week, Profusa had 4 more articles in the media than Venus Concept. MarketBeat recorded 4 mentions for Profusa and 0 mentions for Venus Concept. Profusa's average media sentiment score of 0.98 beat Venus Concept's score of 0.00 indicating that Profusa is being referred to more favorably in the media.

Company	Overall Sentiment
Profusa	Positive
Venus Concept	Neutral

Summary

Profusa beats Venus Concept on 7 of the 12 factors compared between the two stocks.

How does Profusa compare to Nuwellis?

Profusa (NASDAQ:PFSA) and Nuwellis (NASDAQ:NUWE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Profusa has a net margin of 0.00% compared to Nuwellis' net margin of -214.90%. Profusa's return on equity of 0.00% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,348.07%
Nuwellis	-214.90%	-32,351.83%	-249.08%

9.8% of Profusa shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 0.8% of Profusa shares are held by insiders. Comparatively, 1.6% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Nuwellis has higher revenue and earnings than Profusa. Nuwellis is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	N/A	N/A	-$35.82M	-$4.24 thousand	N/A
Nuwellis	$8.77M	0.32	-$17.52M	-$2.24 thousand	N/A

In the previous week, Profusa had 1 more articles in the media than Nuwellis. MarketBeat recorded 4 mentions for Profusa and 3 mentions for Nuwellis. Profusa's average media sentiment score of 0.98 beat Nuwellis' score of 0.00 indicating that Profusa is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profusa	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuwellis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Profusa has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, Nuwellis has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Summary

Profusa beats Nuwellis on 7 of the 12 factors compared between the two stocks.

Get Profusa News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PFSA vs. The Competition

Export

Metric	Profusa	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$179K	$5.80B	$7.01B	$13.00B
Dividend Yield	N/A	1.78%	2.58%	10.20%
P/E Ratio	0.00	24.26	271.11	25.19
Price / Sales	N/A	62.04	595.59	79.93
Price / Cash	N/A	33.10	71.81	50.72
Price / Book	0.00	5.70	13.25	6.22
Net Income	-$35.82M	$148.58M	$3.45B	$342.66M
7 Day Performance	-9.17%	4.75%	4.67%	4.41%
1 Month Performance	-62.09%	0.71%	-1.28%	-1.10%
1 Year Performance	N/A	4.93%	77.33%	23.99%

Profusa Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PFSA Profusa	1.316 of 5 stars	$0.96 +2.5%	N/A	N/A	$179K	N/A	N/A	2	Gap Down
DYNT Dynatronics	N/A	N/A	N/A	N/A	$653K	$33.60M	N/A	200
BIOL BIOLASE	N/A	N/A	N/A	N/A	$581K	$48.83M	N/A	160
RBOT Vicarious Surgical	N/A	$0.07 +0.3%	$7.00 +9,359.5%	-99.3%	$527K	N/A	N/A	210	Upcoming Earnings Gap Down
VERO Venus Concept	N/A	$0.31 flat	N/A	N/A	$442K	$58.88M	N/A	410

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PFSA) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Profusa (PFSA) Competitors